Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
ALPHAMAB-B: KN026 Neoadjuvant Treatment Selected for Presentation at 2026 ASCO Annual Meeting
Recommend 11 Positive 11 Negative 3 |
||||
|
||||
|
ALPHAMAB-B (09966.HK) announced that the results from a phase III clinical study of KN026, co-developed with CSPC PHARMA (01093.HK)'s subsidiary, in combination with the docetaxel (albumin-bound) for injection (HB1801) as neoadjuvant treatment for human epidermal growth factor receptor 2-positive breast cancer have been selected for presentation at LBA Oral Presentation Session of 2026 annual meeting of American Society of Clinical Oncology. The study is led by Professor Shao Zhimin of Fudan University Shanghai Cancer Center as the principal investigator. This marks a major milestone for China-originated innovative therapies on the international academic stage. Auto-translated by AI This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. More Details
AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
